Published in final edited form as:

Org Biomol Chem. 2018 July 18; 16(28): 5144–5149. doi:10.1039/c8ob00949j.

Copper-catalyzed oxidative cross-dehydrogenative coupling of 2*H*-chromenes and terminal alkynes†

Fei Yang^{a,b}, Yangshan Li^a, Paul E. Floreancig^b, Xiaoyan Li^a, and Lei Liu^a

^aSchool of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China

^bDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States

Abstract

An efficient copper-catalyzed cross-dehydrogenative coupling of 2*H*-chromenes and terminal alkynes mediated by DDQ has been established. Protic additive EtOH proved to be crucial to harmonizing the oxidation with subsequent alkynylation step by retaining the oxidation state of oxocarbenium ion in the form of acetal. The CDC reaction exhibits good substrate scope, with a range of terminal aryl- and alkyl alkynes well tolerated. The copper-catalyzed alkynylation of 2*H*-chromene acetals with terminal alkynes were also explored.

Introduction

α -Substituted 2*H*-chromenes and their analogs represent common structural motifs in numerous biologically active natural products and synthetic pharmaceuticals exhibiting antipsychotic, antibacterial, antifungal, antiviral, anticancer, antioxidative, antidepressive, antihypertensive, and antidiabetic activities.¹ Given the significance of this privileged motif in modern pharmacology, developing an efficient, economic, and modular method to its synthesis is of paramount importance.² Nucleophilic substitution of 2*H*-chromene acetals has been recognized as one of the most versatile protocols to access the substructures bearing diverse α -substituent patterns.^{3–7} Elegant methods have been established to install diversely hybridized carbon-centered moieties into the α -position of the skeleton. For examples, Schaus disclosed a chiral Brønsted acid-catalyzed enantioselective vinylation and arylation of 2*H*-chromene acetals with corresponding boronate esters with excellent enantiocontrol.³ Moreover, the Doyle group developed a nickel-catalyzed coupling of chromene acetals with aryl boronic acids in high efficiency.⁴ Watson reported the catalytic enantio selective alkynylation of 2*H*-chromene acetals with a variety of terminal alkynes in the presence of a combination of BF₃·OEt₂ and dicyclohexyl methyl amine.⁵ Rueping and co-workers reported an asymmetric alkylation of 2*H*-chromene acetals with aldehydes by adopting a synergistic catalytic strategy.⁶

†Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/b000000x/

Conflicts of interest

There are no conflicts to declare.

Albeit great innovations, at least one of the two coupling components requires prefunctionalizations.⁸ The direct cross-dehydrogenative coupling (CDC) of 2*H*-chromenes with readily available C–H components represents an ideal synthetic strategy with a minimal amount of intermediary refunctionalizations and with high atom economy.^{9,10} In this context, we have reported CDC reactions of 2*H*-chromenes with 1,3-dicarbonyl compounds¹¹ and electron-rich arenes,¹² providing respective alkylation and arylation compounds. However, the corresponding CDC of 2*H*-chromenes with terminal alkynes has never been established to date, which might be ascribed to their relatively weak nucleophilicity compared to 1,3-dicarbonyl compounds and electron-rich arenes.¹³ In addition, alkyne moieties are pervasive structural elements in chemistry, biology, material science, and medicine, and serve as versatile handles for a variety of functional groups. Particularly, replacing the complicated α -substitutions of anticancer alkaloids with simple alkyne moieties has recently been demonstrated as a practical strategy to maintain the intrinsic biological activity while simplifying the whole synthesis.¹⁴ Therefore, a practical and efficient CDC of 2*H*-chromenes with terminal alkynes to rapidly access a multitude of α -substituted chromene analogs remains highly desired.

Results and discussion

Initially, the CDC of 2*H*-chromene **1a** and phenylacetylene **2a** using DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) as the oxidant was selected as the model reaction for optimization (Table 1). No expected alkynylation product **3a** was observed when CuBr was employed as the catalyst (entry 1, Table 1). Since DDQ has been demonstrated to effect the oxidation of **1a**,¹¹ such observation might be ascribed to the low stability of oxidized oxocarbenium intermediate towards the subsequent capture by **2a**. We envisioned that a protic additive might be beneficial to harmonize the oxidation with subsequent alkynylation.¹⁵ When one equiv of EtOH was introduced, desired **3a** was isolated in 8% yield (entry 2, Table 1). The reaction at 80 °C afforded an improved yield of 21% (entry 3, Table 1). Next, an extensive investigation of different copper catalysts revealed Cu(CN)₄PF₆ as the ideal choice, furnishing **3a** in 60% yield (entries 4–10, Table 1). Other protic additives like MeOH and ⁱPrOH did not provide better results (entries 10–12, Table 1). The reaction proved to be highly dependent on the solvent choice; performing the oxidation in CH₂Cl₂ and subsequent coupling in toluene gave the expected **3a** in 80% yield (entry 13, Table 1). The use of K₂CO₃ as the additive was found to be beneficial for improving the yield to 82% (entry 14, Table 1). Inferior results were obtained when other common oxidants for CDC reactions including PhI(OAc)₂, Na₂S₂O₈, MnO₂, and *tert*-butyl hydroperoxide (TBHP) were used (entry 15, Table 1).

With the optimized reaction condition in hand, we investigated the scope of the CDC of 2*H*-chromenes with terminal alkynes (Scheme 1). The reaction proved to be fairly general for a variety of electronically varied aryl acetylenes with different substituent patterns (**3a–3i**). Electron-donating moieties (**3b–3d**) together with electron-withdrawing halides (**3e–3h**) and trifluoromethyl (**3i**) ones were well tolerated with up to 85% yield. 2-Naphthyl acetylene (**3j**) and heteroaryl acetylenes (**3k** and **3l**) were viable coupling components. Besides arylacetylenes, alkyl acetylene was also found to be compatible with the CDC reaction, as

demonstrated by the generation of **3m** in 63% yield. The CDC of electronically varied 2*H*-chromenes with different substituent patterns with and diverse aryl acetylenes proceeded smoothly, providing **3n-3s** in high efficiency. The mild CDC reaction exhibits good functional group compatibility for further manipulations.

During the standard CDC reaction of **1a** with **2a**, a considerable amount of an intermediate was observed by TLC analysis, which was identified as EtOH adduct acetal **4** (Scheme 2). Accordingly, a control experiment was performed to explore the role of EtOH by subjecting **4** to the standard CDC conditions (Scheme 2). Comparable yields to those of CDC processes were obtained, suggesting that acetal **4** might be an intermediate for the CDC process.

The DDQ-mediated oxidation of 2*H*-chromenes was significantly suppressed by adding stoichiometric amount of radical inhibitor 2,6-di-*tert*-butyl-4-methylphenol (BHT) or TEMPO, thus indicating that a radical intermediate might be involved. Based on these preliminary studies, a plausible mechanism was proposed (Scheme 3). 2*H*-chromene **1a** might undergo a single electron transfer (SET) to DDQ giving radical cation **5**, which then proceeds through a hydrogen atom abstraction or proton abstraction followed by a SET to generate α,β -unsaturated oxocarbenium intermediate **6**.¹⁶ A stoichiometric protic additive EtOH rapidly capture **6** to give 2*H*-chromene acetal **4** for subsequent alkynylation.

Conclusions

In conclusion, an efficient copper-catalyzed CDC of 2*H*-chromenes and terminal alkynes using DDQ as the oxidant is described. Protic additive EtOH proved to be crucial to harmonizing the oxidation with subsequent alkynylation step by retaining the oxidation state of oxocarbenium ion in the form of acetal. The copper-catalyzed alkynylation of 2*H*-chromene acetals with terminal alkynes were also explored. Ongoing studies focus on the developing the catalytic asymmetric variant of on the discovery of biologically important small molecules.

Experimental

Proton (¹H NMR) and carbon (¹³C NMR) nuclear magnetic resonance spectra were recorded at 500 MHz and 125 MHz, respectively. The chemical shifts are given in parts per million (ppm) on the delta (δ) scale. The solvent peak was used as a reference value, for ¹H NMR: CDCl₃ = 7.27 ppm, for ¹³C NMR: CDCl₃ = 77.23 ppm. Analytical TLC was performed on precoated silica gel GF254 plates. HRMS were carried out using an Orbitrap analyzer.

General procedure for the oxidative C–H alkynylation of 2*H*-chromenes (Scheme 1)

To a solution of 2*H*-chromene **1a** (0.1 mmol, 1.0 eq) in CH₂CE (0.5 mL) was added EtOH (0.14 mmol, 1.4 eq) and DDQ (0.12 mmol, 1.2 eq) successively at rt. The mixture was stirred at that temperature under N₂ atmosphere until all the **1a** disappeared monitored by TLC. Then toluene (1.2 mL) was added and volatiles were removed under reduced pressure. After that, Cu(CN)₄PF₆ (0.01 mmol, 10 mol%), K₂CO₃ (0.03 mmol, 0.3 eq), and terminal alkyne (0.15 mmol, 1.5 eq) were added, and the mixture was stirred at 80 °C for 5 h. The volatiles were removed under reduced pressure and the residue was purified by flash

chromatography on silica gel using EtOAc/petroleum ether (5 : 95) as an eluent to give the desired product.

2-(Phenylethynyl)-2H-chromene (3a)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3a** as a light yellow oil (19.0 mg, 82% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.46–7.40 (m, 2H), 7.33–7.27 (m, 3H), 7.17 (td, J = 7.9, 1.2 Hz, 1H), 7.07–7.02 (m, 1H), 6.97–6.88 (m, 2H), 6.53 (d, J = 9.4 Hz, 1H), 5.85 (dd, J = 9.5, 4.0 Hz, 1H), 5.83–5.79 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.6, 132.1, 129.7, 128.8, 128.4, 126.9, 124.8, 122.3, 122.2, 122.0, 121.6, 116.6, 86.2, 85.9, 65.2; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{13}\text{O}$: 233.0961, found 233.0976.

2-(*p*-Tolylethynyl)-2H-chromene (3b)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3b** as a yellow oil (19.2 mg, 78% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.36–7.30 (m, 2H), 7.20–7.15 (m, 1H), 7.10 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 7.2 Hz, 1H), 6.93 (t, J = 7.4 Hz, 2H), 6.52 (d, J = 9.5 Hz, 1H), 5.86 (dd, J = 9.5, 3.9 Hz, 1H), 5.83–5.79 (m, 1H), 2.34 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.6, 139.0, 132.0, 129.6, 129.1, 126.9, 124.7, 122.4, 121.9, 121.6, 119.2, 116.6, 86.0, 85.5, 65.3, 21.6; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{15}\text{O}$: 247.1117, found 247.1110.

2-(*m*-Tolylethynyl)-2H-chromene (3c)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3c** as a light yellow oil (18.6 mg, 76% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.26–7.21 (m, 2H), 7.20–7.14 (m, 2H), 7.12 (d, J = 7.7 Hz, 1H), 7.04 (dd, J = 7.4, 1.6 Hz, 1H), 6.95–6.89 (m, 2H), 6.52 (dd, J = 9.5, 0.8 Hz, 1H), 5.85 (dd, J = 9.5, 4.0 Hz, 1H), 5.80 (dd, J = 4.0, 1.5 Hz, 1H), 2.30 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.6, 138.0, 132.6, 129.7, 129.6, 129.1, 128.2, 126.9, 124.7, 122.3, 122.1, 121.9, 121.6, 116.6, 86.0, 85.8, 65.2, 21.3; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{15}\text{O}$: 247.1117, found 247.1122.

2-((4-Methoxyphenyl)ethynyl)-2H-chromene (3d)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3d** as a light yellow oil (16.2 mg, 62% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.40–7.33 (m, 2H), 7.15 (td, J = 7.8, 1.6 Hz, 1H), 7.03 (dd, J = 7.4, 1.5 Hz, 1H), 6.95–6.87 (m, 2H), 6.84–6.77 (m, 2H), 6.51 (d, J = 9.5 Hz, 1H), 5.84 (dd, J = 9.5, 3.9 Hz, 1H), 5.79 (dd, J = 3.9, 1.5 Hz, 1H), 3.79 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 160.0, 152.7, 133.6, 129.6, 126.9, 124.7, 122.5, 121.9, 121.6, 116.6, 114.0, 113.3, 85.9, 84.9, 65.4, 55.4; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{15}\text{O}_2$: 263.1067, found 263.1059.

2-((4-Bromophenyl)ethynyl)-2H-chromene (3e)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3e** as a light yellow oil (25.6 mg, 83% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.42 (d, *J* = 8.3 Hz, 2H), 7.31–7.27 (m, 2H), 7.17 (t, *J* = 7.6 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.97–6.86 (m, 2H), 6.52 (d, *J* = 9.5 Hz, 1H), 5.88–5.76 (m, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 152.5, 133.5, 132.1, 131.7, 129.7, 128.4, 127.0, 124.9, 123.2, 122.0, 121.4, 116.6, 87.3, 84.8, 65.1; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₇H₁₂BrO: 311.0066, found 311.0061.

2-((4-Chlorophenyl)ethynyl)-2H-chromene (3f)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3f** as a light yellow oil (22.2 mg, 84% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.36–7.31 (m, 2H), 7.27–7.23 (m, 2H), 7.16 (td, *J* = 7.8, 1.6 Hz, 1H), 7.04 (dd, *J* = 7.4, 1.5 Hz, 1H), 6.95–6.88 (m, 2H), 6.52 (d, *J* = 9.4 Hz, 1H), 5.83 (dd, *J* = 9.4, 4.0 Hz, 1H), 5.79 (dd, *J* = 4.0, 1.3 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 152.5, 134.9, 133.3, 129.7, 128.7, 127.0, 124.9, 122.0, 121.9, 121.5, 120.8, 116.6, 87.2, 84.7, 65.1; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₇H₁₂ClO: 267.0571, found 267.0578.

2-((4-Fluorophenyl)ethynyl)-2H-chromene (3g)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3g** as a light yellow oil (20.7 mg, 83% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.43–7.38 (m, 2H), 7.17 (td, *J* = 7.8, 1.6 Hz, 1H), 7.05 (dd, *J* = 7.4, 1.6 Hz, 1H), 7.01–6.96 (m, 2H), 6.95–6.89 (m, 2H), 6.53 (d, *J* = 9.5 Hz, 1H), 5.84 (dd, *J* = 9.5, 4.0 Hz, 1H), 5.80 (dd, *J* = 4.0, 1.4 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 163.8, 161.9, 152.5, 134.0, 129.7, 127.0, 124.8, 122.0, 121.5, 118.4, 116.6, 115.7, 85.9, 84.8, 65.1; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₇H₁₂FO: 251.0867, found 251.0875.

2-((3-Fluorophenyl)ethynyl)-2H-chromene (3h)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3h** as a light yellow oil (21.2 mg, 85% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.26–7.22 (m, 1H), 7.22–7.15 (m, 2H), 7.12 (ddd, *J* = 9.4, 2.4, 1.3 Hz, 1H), 7.05 (dd, *J* = 7.5, 1.5 Hz, 1H), 7.04–6.99 (m, 1H), 6.97–6.89 (m, 2H), 6.53 (d, *J* = 9.5 Hz, 1H), 5.84 (dd, *J* = 9.5, 4.0 Hz, 1H), 5.80 (dd, *J* = 4.0, 1.4 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 163.3, 161.4, 152.4, 130.0, 129.7, 127.9, 127.0, 125.0, 124.1, 122.0, 121.5, 118.9, 116.6, 116.2, 87.1, 84.5, 65.0; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₇H₁₂FO: 251.0867, found 251.0870.

2-((4-(Trifluoromethyl)phenyl)ethynyl)-2H-chromene (3i)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3i** as a light yellow oil (24.0 mg, 80% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.53 (q, *J* = 8.5 Hz, 4H), 7.19 (td, *J* = 7.9, 1.4 Hz, 1H), 7.06 (dd, *J* = 7.4, 1.3 Hz, 1H), 6.94 (dd, *J* = 14.1, 7.7 Hz, 2H),

6.55 (d, J = 9.2 Hz, 1H), 5.84 (dt, J = 8.0, 4.4 Hz, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.4, 132.3, 130.5, 129.8, 127.0, 126.1, 125.3, 125.1, 122.9, 122.1, 121.6, 121.4, 116.6, 88.6, 84.4, 65.0; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{12}\text{F}_3\text{O}$: 301.0835, found 301.0832.

2-(Naphthalen-2-ylethynyl)-2H-chromene (3j)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3j** as a light yellow oil (22.0 mg, 78% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.97 (s, 1H), 7.82–7.76 (m, 2H), 7.75 (d, J = 8.2 Hz, 1H), 7.52–7.45 (m, 3H), 7.19 (td, J = 7.8, 1.6 Hz, 1H), 7.07 (dd, J = 7.7, 1.6 Hz, 1H), 6.99–6.92 (m, 2H), 6.56 (d, J = 9.1 Hz, 1H), 5.93–5.85 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.6, 133.1, 132.9, 132.2, 129.7, 128.6, 128.0, 127.9, 127.9, 127.0, 126.7, 124.8, 122.2, 122.0, 121.6, 119.6, 116.7, 86.5, 86.2, 65.3; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{21}\text{H}_{15}\text{O}$: 283.1117, found 283.1110.

2-(Thiophen-2-ylethynyl)-2H-chromene (3k)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3k** as a light yellow oil (16.2 mg, 68% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.26 (d, J = 4.5 Hz, 1H), 7.22 (d, J = 3.5 Hz, 1H), 7.17 (td, J = 7.9, 1.4 Hz, 1H), 7.05 (dd, J = 7.4, 1.3 Hz, 1H), 6.93 (dt, J = 15.8, 6.6 Hz, 3H), 6.56–6.50 (m, 1H), 5.87–5.80 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.5, 133.1, 129.7, 127.9, 127.1, 127.0, 124.9, 122.2, 122.0, 121.7, 121.4, 116.6, 90.1, 79.2, 65.3; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{15}\text{H}_{11}\text{OS}$: 239.0525, found 239.0520.

2-(Thiophen-3-ylethynyl)-2H-chromene (3l)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3l** as a light yellow oil (16.6 mg, 70% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.46 (dd, J = 2.9, 0.9 Hz, 1H), 7.23 (dd, J = 5.0, 3.0 Hz, 1H), 7.17 (td, J = 7.8, 1.5 Hz, 1H), 7.10 (dd, J = 5.0, 1.0 Hz, 1H), 7.05 (dd, J = 7.4, 1.4 Hz, 1H), 6.96–6.88 (m, 2H), 6.52 (d, J = 9.4 Hz, 1H), 5.84 (dd, J = 9.5, 4.0 Hz, 1H), 5.80 (dd, J = 4.0, 1.3 Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.5, 130.1, 129.9, 129.7, 126.9, 125.4, 124.8, 122.1, 122.0, 121.5, 121.3, 116.6, 85.8, 81.0, 65.2; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{15}\text{H}_{11}\text{OS}$: 239.0525, found 239.0536.

2-(Oct -1-yn-1-yl)-2H-chromene (3m)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3m** as a light yellow oil (15.1 mg, 63% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.14 (td, J = 7.9, 1.6 Hz, 1H), 7.01 (dd, J = 7.4, 1.5 Hz, 1H), 6.93–6.85 (m, 2H), 6.45 (dd, J = 9.6, 0.9 Hz, 1H), 5.75 (dd, J = 9.6, 3.8 Hz, 1H), 5.58–5.53 (m, 1H), 2.20 (td, J = 7.2, 2.0 Hz, 2H), 1.52–1.44 (m, 2H), 1.38–1.18 (m, 6H), 0.87 (t, J = 7.0 Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.7, 129.5, 126.8, 124.3, 123.1, 121.8, 121.7, 116.6, 87.3, 65.1, 31.4, 28.6, 28.5, 22.6, 18.9, 14.2; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{21}\text{O}$: 241.1587, found 241.1596.

2-((4-Methoxyphenyl)ethynyl)-6-methyl-2H-chromene (3n)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3n** as a light yellow oil (19.3 mg, 70% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.33 (d, *J* = 8.1 Hz, 2H), 7.09 (d, *J* = 7.9 Hz, 2H), 6.97 (dd, *J* = 8.1, 1.6 Hz, 1H), 6.86 (d, *J* = 1.4 Hz, 1H), 6.82 (d, *J* = 8.2 Hz, 1H), 6.48 (d, *J* = 9.5 Hz, 1H), 5.84 (dd, *J* = 9.5, 3.9 Hz, 1H), 5.77 (dd, *J* = 3.9, 1.5 Hz, 1H), 2.34 (s, 3H), 2.28 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 150.4, 138.9, 132.0, 131.1, 130.0, 129.1, 127.4, 124.8, 122.4, 121.4, 119.3, 116.3, 85.9, 85.6, 65.2, 21.6, 20.7; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₉H₁₇O₂: 277.1223, found 277.1231.

6-Methyl-2-(*p*-tolylethynyl)-2H-chromene (3o)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3o** as a light yellow oil (21.5 mg, 83% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.38–7.34 (m, 2H), 6.96 (dd, *J* = 8.1, 1.8 Hz, 1H), 6.85 (d, *J* = 1.7 Hz, 1H), 6.83–6.78 (m, 3H), 6.47 (dd, *J* = 9.5, 1.1 Hz, 1H), 5.83 (dd, *J* = 9.5, 3.9 Hz, 1H), 5.75 (dd, *J* = 3.9, 1.6 Hz, 1H), 3.79 (s, 3H), 2.27 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 160.0, 150.5, 133.6, 131.1, 130.0, 127.4, 124.8, 122.5, 121.4, 116.3, 114.4, 114.0, 85.8, 85.0, 65.3, 55.4, 20.7; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₉H₁₇O: 261.1274, found 261.1270.

2-((4-Bromophenyl)ethynyl)-6-methyl-2H-chromene (3p)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3p** as a light yellow oil (26.6 mg, 82% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.42 (dd, *J* = 7.7, 1.6 Hz, 2H), 7.31–7.28 (m, 2H), 6.96 (dd, *J* = 8.1, 1.6 Hz, 1H), 6.86 (s, 1H), 6.81 (d, *J* = 8.1 Hz, 1H), 6.49 (d, *J* = 9.5 Hz, 1H), 5.84 (dd, *J* = 9.5, 4.0 Hz, 1H), 5.77 (dd, *J* = 3.9, 1.5 Hz, 1H), 2.27 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 150.4, 132.1, 131.2, 130.1, 128.8, 128.3, 127.4, 124.9, 122.4, 122.3, 121.4, 116.4, 86.3, 85.7, 65.2, 20.7; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₈H₁₄BrO: 325.0223, found 325.0216.

2-((4-Chlorophenyl)ethynyl)-6-methyl-2H-chromene (3q)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3q** as a light yellow oil (24.0 mg, 86% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.37–7.31 (m, 2H), 7.27–7.22 (m, 2H), 6.96 (dd, *J* = 8.1, 1.3 Hz, 1H), 6.85 (s, 1H), 6.81 (d, *J* = 8.2 Hz, 1H), 6.48 (d, *J* = 9.5 Hz, 1H), 5.82 (dd, *J* = 9.5, 4.0 Hz, 1H), 5.75 (dd, *J* = 3.9, 1.2 Hz, 1H), 2.27 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 150.3, 134.9, 133.3, 131.3, 130.2, 128.7, 127.4, 125.1, 122.0, 121.3, 120.8, 116.3, 87.3, 84.5, 65.1, 20.7; HRMS (EI) *m/z* [M + H]⁺ calculated for C₁₈H₁₄ClO: 281.0728, found 281.0720.

7-Methoxy-2-(phenylethynyl)-2H-chromene (3r)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3r** as a light yellow oil (19.8 mg, 76% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.48–7.40 (m, 2H),

7.35–7.27 (m, 3H), 6.96 (d, J = 8.1 Hz, 1H), 6.57–6.42 (m, 3H), 5.79 (dd, J = 3.9, 1.5 Hz, 1H), 5.72 (dd, J = 9.5, 4.0 Hz, 1H), 3.80 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 161.1, 154.0, 132.2, 128.9, 128.4, 127.7, 124.6, 122.5, 119.3, 115.0, 108.0, 102.5, 86.5, 85.8, 65.5, 55.6; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{15}\text{O}_2$: 263.1067, found 263.1057.

6-Bromo-2-(phenylethynyl)-2H-chromene (3s)

It was prepared following the general procedure and purified by flash chromatography on silica gel using ethyl acetate/petroleum ether (5 : 95) as an eluent to afford **3s** as a light yellow oil (21.6 mg, 70% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.47–7.39 (m, 2H), 7.36–7.27 (m, 3H), 7.27–7.24 (m, 1H), 7.17 (d, J = 2.4 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 6.46 (d, J = 9.6 Hz, 1H), 5.90 (dd, J = 9.6, 4.1 Hz, 1H), 5.80 (dd, J = 4.1, 1.5 Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 151.7, 132.3, 132.2, 129.5, 129.0, 128.5, 123.8, 123.5, 123.5, 122.2, 118.5, 114.1, 86.4, 85.6, 65.4; HRMS (EI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{12}\text{BrO}$: 311.0066, found 311.0075.

General procedure for the alkylation of 2H-chromenes (Scheme 2)

To a solution of 2H-chromene **4** (0.1 mmol, 1.0 eq) in toluene (1.0 mL) was added $\text{Cu}(\text{CN})_4\text{PF}_6$ (0.01 mmol, 10 mol%) and terminal alkyne (0.15 mmol, 1.5 eq). The mixture was stirred at 80 °C for 3 h before the volatiles were removed under reduced pressure. The residue was purified by flash chromatography on silica gel using EtOAc/petroleum ether (5 : 95) as an eluent to give the desired product.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the National Science Foundation of China (21722204 and 21472112), the National Institutes of Health (R01GM103886), and the Fok Ying Tung Education Foundation (151035).

References

- (a) Lu Z, Lin Z, Wang W, Du L, Zhu T, Fang Y, Gu Q, Zhu W. *J Nat Prod.* 2008; 71:543. [PubMed: 18281952] (b) Pan L, Matthew S, Lantvit DD, Zhang X, Ninh TN, Chai H, Blanco EJ Carcache de, Soejarto DD, Swanso SM, Kinghorn AD. *J Nat Prod.* 2011; 74:2193. [PubMed: 21973101] (c) Maneerat W, Ritthiwigrom T, Cheenpracha S, Promgool T, Yossathera K, Deachathai S, Phakhodee W, Laphookhieo S. *J Nat Prod.* 2012; 75:741. [PubMed: 22482432] (d) Gumula I, Alao JP, Ndiege IO, Sunnerhagen P, Yenesew A, Erdlyi M. *J Nat Prod.* 2014; 77:2060. [PubMed: 25226568] (e) TenBrink RE, Bergh CL, Duncan JN, Harris DW, Huff RM, Lahti RA, Lawson CF, Lutzke BS, Martin IJ, Rees SA, Schlachter SK, Sih JC, Smith MW. *J Med Chem.* 1996; 39:2435. [PubMed: 8691438] (f) Clarke RL, Harris LS. *J Med Chem.* 1962; 5:77. (g) Albrecht U, Lalk M, Langer P. *Bioorg Med Chem.* 2005; 13:1531. [PubMed: 15698769] (h) Sawadjoon S, Kittakoo P, Kirtikara K, Vichai V, Tanticharoen M, Thebtaranonth Y. *J Org Chem.* 2002; 67:5470. [PubMed: 12153244] (i) Bauer DJ, Selway JWT, Batchelor JF, Tisdale M, Caldwell IC, Young DAB. *Nature.* 1981; 292:369. [PubMed: 6265792] (j) Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F. *J Med Chem.* 1997; 40:2117. [PubMed: 9216828] (k) Schneider P, Hawser S, Islam K. *Bioorg Med Chem Lett.* 2003; 13:4217. [PubMed: 14623005]

2. (a) Welsch ME, Snyder SA, Stockwell BR. *Curr Opin Chem Biol.* 2010; 14:347. [PubMed: 20303320] (b) Nicolaou KC, Pfeifferkorn JA, Roecker AJ, Cao GQ, Barluenga S, Mitchell HJ. *J Am Chem Soc.* 2000; 122:9939. (c) Zhang H, Wang K, Wang B, Yi H, Hu F, Li C, Zhang Y, Wang J. *Angew Chem Int Ed.* 2014; 53:13234. (d) Xia Y, Xia Y, Zhang Y, Wang J. *Org Biomol Chem.* 2014; 12:9333. [PubMed: 25327448]
3. (a) Moquist PN, Kodama T, Schaus SE. *Angew Chem Int Ed.* 2010; 49:7096. (b) Luan Y, Barbato KS, Moquist PN, Kodama T, Schaus SE. *J Am Chem Soc.* 2015; 137:3233. [PubMed: 25715172]
4. (a) Graham TJA, Doyle AG. *Org Lett.* 2012; 14:1616. [PubMed: 22385385] (b) Sylvester KT, Wu K, Doyle AG. *J Am Chem Soc.* 2012; 134:16967. [PubMed: 23030789]
5. (a) Maity P, Srinivas HD, Watson MP. *J Am Chem Soc.* 2011; 133:17142. [PubMed: 21988178] (b) Srinivas HD, Maity P, Yap GPA, Watson MP. *J Org Chem.* 2015; 80:4003. [PubMed: 25847687]
6. Rueping M, Volla CMR, Atodiresei L. *Org Lett.* 2012; 14:4642. [PubMed: 22913599]
7. (a) Wu YC, Li HJ, Liu L, Demoulin N, Liu Z, Wang D, Chen Y-J. *Adv Synth Catal.* 2011; 353:907. (b) Gil-Negrete JM, Sestelo JP, Sarandeses LA. *Org Lett.* 2016; 18:4316. [PubMed: 27530143] (c) Qin B, Schneider U. *J Am Chem Soc.* 2016; 138:13119. [PubMed: 27654114]
8. (a) Godula K, Sames D. *Science.* 2006; 312:67. [PubMed: 16601184] (b) Gutekunst WR, Baran PS. *Chem Soc Rev.* 2011; 40:1976. [PubMed: 21298176] (c) Giri R, Shi BF, Engle KM, Mangel N, Yu JQ. *Chem Soc Rev.* 2009; 38:3242. [PubMed: 19847354] (d) Liu C, Zhang H, Shi W, Lei A. *Chem Rev.* 2011; 111:1780. [PubMed: 21344855] (e) Zhang SY, Zhang FM, Tu YQ. *Chem Soc Rev.* 2011; 40:1937. [PubMed: 21286642] (f) Sun CL, Li BJ, Shi ZJ. *Chem Rev.* 2011; 111:1293. [PubMed: 21049955] (g) Yeung CS, Dong VM. *Chem Rev.* 2011; 111:1215. [PubMed: 21391561] (h) Sarhan AAO, Bolm C. *Chem Soc Rev.* 2009; 38:2730. [PubMed: 19690750]
9. (a) Li CJ. *Acc Chem Res.* 2009; 42:335. [PubMed: 19220064] (b) Girard SA, Knauber T, Li CJ. *Angew Chem Int Ed.* 2014; 53:74. (c) Yoo WJ, Li CJ. *Top Curr Chem.* 2010; 292:281. [PubMed: 21500410] (d) Scheuermann CJ. *Chem-Asian J.* 2010; 5:436. [PubMed: 20041458] (e) Rohlmann R, García Mancheño O. *Synlett.* 2013; 6(f) Klussmann M, Sureshkumar D. *Synthesis.* 2011:353. (g) Li CJ, Li Z. *Pure Appl Chem.* 2006; 78:935.
10. (a) Davies HML, Jin Q. *J Am Chem Soc.* 2004; 126:10862. [PubMed: 15339169] (b) Clausen DJ, Floreancig PE. *J Org Chem.* 2012; 77:6574. [PubMed: 22780559] (c) Cui Y, Villafane LA, Clausen DJ, Floreancig PE. *Tetrahedron.* 2013; 69:7618. [PubMed: 23913987] (d) Wu ZJ, Qian J, Wang TT, Huang Z-Z. *Synlett.* 2014; 25:2072.
11. Li F, Meng Z, Hua J, Li W, Lou H, Liu L. *Org Biomol Chem.* 2015; 13:5710. [PubMed: 25897807]
12. Chen W, Xie Z, Zheng H, Lou H, Liu L. *Org Lett.* 2014; 16:5988. [PubMed: 25386987]
13. (a) Correia CA, Li CJ. *Heterocycles.* 2010; 82:555. (b) Xiang S-K, Zhang B, Zhang L-H, Cui Y. *N Jiao.* 2012; 55:50. (c) Wan M, Meng Z, Lou H, Liu L. *Angew Chem Int Ed.* 2014; 53:13845.
14. (a) Xie Z, Liu L, Chen W, Zheng H, Xu Q, Yuan H, Lou H. *Angew Chem Int Ed.* 2014; 53:3904. (b) Zimmermann TJ, Roy S, Martinez NE, Ziegler S, Hedberg C, Waldmann H. *ChemBioChem.* 2013; 14:295. [PubMed: 23364933] (c) Sun X, Liu M, Gao L, Mao Y, Zhao D, Zhuang J, Liu L. *Eur J Med Chem.* 2018; 150:719. [PubMed: 29573707]
15. (a) Meng Z, Sun S, Yuan H, Lou H, Liu L. *Angew Chem Int Ed.* 2014; 53:543. (b) Liu X, Meng Z, Li C, Lou H, Liu L. *Angew Chem Int Ed.* 2015; 54:6012. (c) Sun S, Li C, Floreancig PE, Lou H, Liu L. *Org Lett.* 2015; 17:1684. [PubMed: 25781505] (d) Liu X, Sun S, Meng Z, Lou H, Liu L. *Org Lett.* 2015; 17:2396. [PubMed: 25941891] (e) Xie Z, Zan X, Sun S, Pan X, Liu L. *Org Lett.* 2016; 18:3944. [PubMed: 27483043] (f) Wan M, Sun S, Li Y, Liu L. *Angew Chem Int Ed.* 2017; 56:5116. (g) Lu R, Li Y, Zhao J, Li J, Wang S, Liu L. *Chem Commun.* 2018; 54:4445.
16. Jung HH, Floreancig PE. *Tetrahedron.* 2009; 65:10830. [PubMed: 20640173]

Scheme 1.

The CDC reaction scope. ^aReaction in 1.0 g scale.

Scheme 2.
Alkynylation of 2H-chromene acetals.

Scheme 3.
A proposed mechanism.

Table 1Reaction condition optimization^a

Entry	Catalyst	Additive	Yield ^b (%)
1	CuBr	—	< 5
2	CuBr	EtOH	8
3 ^c	CuBr	EtOH	21
4 ^c	CuBr ₂	EtOH	< 5
5 ^c	CuCl	EtOH	23
6 ^c	CuCl ₂	EtOH	< 5
7 ^c	CuI	EtOH	15
8 ^c	CuOAc	EtOH	< 5
9 ^c	CuCN	EtOH	10
10 ^c	Cu(CN) ₄ PF ₆	EtOH	60
11 ^c	Cu(CN) ₄ PF ₆	MeOH	58
12 ^c	Cu(CN) ₄ PF ₆	<i>i</i> PrOH	41
13 ^a	Cu(CN) ₄ PF ₆	EtOH	80
14 ^{de}	Cu(CN) ₄ PF ₆	EtOH	82
15 ^f	Cu(CN) ₄ PF ₆	EtOH	< 20

^a General conditions: **1a** (0.1 mmol), DDQ (0.11 mmol), and additive (0.11 mmol) in ClCH₂CH₂Cl (1.0 mL) at rt for 1 h, followed by **2a** (0.15 mmol), and catalyst (10 mol%) at rt for 5 h.

^b Isolated yield.

^c Performing the oxidation in ClCH₂CH₂Cl at rt, and coupling in at 80 °C.

^d Performing the oxidation in CH₂Cl₂ (0.5 mL) at rt, followed by alkylation in toluene (1.2 mL) at 80 °C.

^e Reaction with 0.3 equiv of K₂CO₃.

^f PhI(OAc)₂, Na₂S₂O₈, MnO₂, or TBHP as the oxidant.